Recruiting PHASE2 INTERVENTIONAL 6-arm NCT06295159

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Sponsor: Bristol-Myers Squibb

Conditions Advanced Melanoma Melanoma Melanoma Stage III Melanoma Stage IV

Interventions Ipilimumab Nivolumab Nivolumab + Relatlimab

Updated 10 times since 2024 Last updated: Jan 6, 2026 Started: May 17, 2024 Primary completion: Nov 30, 2028 Completion: Nov 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Advanced Melanoma and Melanoma, this trial is actively recruiting participants. The trial is conducted by Bristol-Myers Squibb and has accumulated 10 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE2
Oct 2025 — Feb 2026 [monthly]

Recruiting PHASE2
Jul 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Apr 2025 — Jul 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Apr 2025 [monthly]

Recruiting PHASE2

▶ Show 5 earlier versions

Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE2

Phase: EARLY_PHASE1 → PHASE2
Sep 2024 — Dec 2024 [monthly]

Recruiting EARLY_PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting EARLY_PHASE1
Apr 2024 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
H. Lee Moffitt Cancer Center and Research Institute

Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tampa, United States